LeonaBio (LONA) awards 300,000 stock options to chief scientific officer

Rhea-AI Filing Summary

LeonaBio, Inc. reported that its Chief Scientific Officer, Kevin Church, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.

The award was received as a compensation-related grant, not an open-market purchase or sale. According to the grant terms, the options are scheduled to vest monthly over 48 months, as long as Church continues to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CHURCH KEVIN

Role CHIEF SCIENTIFIC OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	300,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 300,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 300,000 shares Exercise price: $9.54 per share Expiration date: April 8, 2036 +2 more

5 metrics

Option grant size 300,000 shares Stock Option (Right to Buy) granted to CSO

Exercise price $9.54 per share Conversion or exercise price of stock options

Expiration date April 8, 2036 Option expiration for 300,000-share grant

Vesting schedule 48 months, monthly Vests on monthly anniversaries of grant date

Post-grant derivative holdings 300,000 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), 2026 Equity Incentive Plan, Service Provider, Grant, award, or other acquisition

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

2026 Equity Incentive Plan financial

"as defined in the Issuer's 2026 Equity Incentive Plan"

Service Provider financial

"subject to the optionee continuing to be a Service Provider"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHURCH KEVIN

(Last) (First) (Middle)

C/O LEONABIO, INC.

18706 NORTH CREEK PARKWAY, SUITE 104

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.54	04/09/2026		A		300,000		(1)	04/08/2036	Common Stock	300,000	$0	300,000	D

Explanation of Responses:

1. The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.

	/s/ Mark Worthington Attorney-in-Fact for Kevin Church	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did LeonaBio (LONA) disclose for Kevin Church?

LeonaBio disclosed that Chief Scientific Officer Kevin Church received a grant of stock options for 300,000 shares of common stock. This is a compensation-related award, not an open-market trade, and represents his post-transaction derivative holdings from this grant.

What are the key terms of Kevin Church’s LeonaBio stock option grant?

Kevin Church received stock options to acquire 300,000 LeonaBio common shares at an exercise price of $9.54 per share. The options expire on April 8, 2036 and represent a long-dated incentive aligned with his continued service to the company.

How do Kevin Church’s LeonaBio options vest under this Form 4 filing?

The options are scheduled to vest monthly over a 48-month period, based on the monthly anniversaries of the grant date. Vesting is contingent on Church continuing to be a Service Provider under LeonaBio’s 2026 Equity Incentive Plan throughout the applicable vesting dates.

Does the LeonaBio Form 4 for Kevin Church involve any stock sales?

The Form 4 shows no stock sales by Kevin Church. It reports a grant of stock options, coded as an acquisition (transaction code A), meaning he received derivative rights to buy shares rather than buying or selling shares on the open market.

What does the expiration date mean for Kevin Church’s LeonaBio options?

The options expire on April 8, 2036, meaning Church must exercise them on or before that date to acquire shares at $9.54. After expiration, any unexercised portions of the 300,000-share grant will lapse and no longer be exercisable.